Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): Updated analysis from KarMMa-3 Meeting Abstract
| Authors: | Scheid, C.; Rodriguez-Otero, P.; Ailawadhi, S.; Arnulf, B.; Patel, K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N.; Costa, L. J.; Vij, R.; Bahlis, N. J.; Moreau, P.; Solomon, S. R.; Abrahamsen, I. W.; Baz, R.; Broijl, A.; Chen, C.; Jagannath, S.; Raje, N.; Delforge, M.; Benjamin, R.; Pabst, T.; Iida, S.; Berdeja, J.; Truppel-Hartmann, A.; Bhatnagar, R.; Wu, F.; Piasecki, J.; Eliason, L.; Dhanda, D.; Felten, J.; Caia, A.; Cook, M.; McKiver, M. P.; Giralt, S. |
| Abstract Title: | Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): Updated analysis from KarMMa-3 |
| Meeting Title: | 36. Deutscher Krebskongress - Fortschritt gemeinsam gestalten |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 47 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Feb 21-24 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2024-02-01 |
| Start Page: | 247 |
| End Page: | 248 |
| Language: | English |
| ACCESSION: | WOS:001332646400610 |
| PROVIDER: | wos |
| DOI: | 10.1159/000535363 |
| Notes: | Meeting Abstract: 1060 -- 'The 36th German Cancer Congress - Building Progress Together' -- Located in the section 'Novel Therapeutics: Targeted Therapies, Immunotherapies, Cellular Therapies' (Late Breaking) -- Source: Wos |
